Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people(1). Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Min, Nettles, Richard E., Belema, Makonen, Snyder, Lawrence B., Nguyen, Van N., Fridell, Robert A., Serrano-Wu, Michael H., Langley, David R., Sun, Jin-Hua, O’Boyle II, Donald R., Lemm, Julie A., Wang, Chunfu, Knipe, Jay O., Chien, Caly, Colonno, Richard J., Grasela, Dennis M., Meanwell, Nicholas A., Hamann, Lawrence G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094952/
https://www.ncbi.nlm.nih.gov/pubmed/20410884
http://dx.doi.org/10.1038/nature08960

Ejemplares similares

Ejemplares similares